News

Publication of a clinical phase 2 study of SCO-792

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activator

Publication of medicinal chemistry research on SCO-792, an enteropeptidase inhibitor

Awarded the 3rd prize of the Boehringer Ingelheim Innovation Prize, 2021

IP6K inhibitor（SCO-006）information has been updated

Publication of a preclinical study: Inositol hexakisphosphate kinase (IP6K) is crucial in regulating plasma phosphate levels in vivo, and SCO-006-mediated IP6K inhibition is a potential novel treatment strategy against hyperphosphatemia

Publication of a clinical phase 1 study: SCO-267, a GPR40 full agonist, is safe and well-tolerated, exhibits good potential for once-daily dosing, and improves glycemic control in humans

The clinical results of SCO-267 was presented at the Virtual 81st Scientific Sessions – American Diabetes Association: First report on the clinical data of a GPR40 full agonist in the phase 1 trial

Huadong and SCOHIA PHARMA Announce Strategic Collaboration to Develop, Manufacture and Commercialize SCO-094 in Asia Pacific

SCOHIA initiates a phase 1 study on an SSTR5 antagonist (SCO-240)